Should you consider using **BAMLANIVIMAB** to treat your COVID patient

**IS YOUR PATIENT...**

- SARS-CoV-2 positive
- 12 years of age or older
- 40 kg (88.2 lbs.) or heavier
- at high risk for severe COVID-19
- at high risk for hospitalization

**HIGH RISK PATIENTS ARE PATIENTS WHO...**

- have a BMI greater than 35
- have chronic kidney disease
- have diabetes
- have immunosuppressive disease
- are currently receiving immunosuppressive treatment
- are 65 years of age or older
- are 55 years of age or older AND have...
  - cardiovascular disease OR
  - hypertension OR
  - chronic obstructive pulmonary disease (or other chronic respiratory disease)

- are 12 to 17 years of age AND have...
  - a BMI greater than the 85th percentile for their age and gender OR
  - sickle cell disease OR
  - congenital or acquired heart disease OR
  - neurodevelopmental disorders OR
  - a medical-related technological dependence (tracheostomy, gastrostomy, or positive pressure ventilation unrelated to COVID-19) OR
  - asthma, reactive airway, or other chronic respiratory disease requiring daily medication to control

**DO NOT use **BAMLANIVIMAB** if your patient...**

- is already hospitalized due to COVID-19
- requires oxygen therapy due to COVID-19
- requires an increase in baseline oxygen due to COVID-19 and is already on chronic oxygen therapy due to underlying comorbidities unrelated to COVID-19

**WHAT ELSE DO YOU NEED TO KNOW?**

- **BAMLANIVIMAB** has been authorized by the FDA for emergency use only
- **BAMLANIVIMAB** is authorized only while emergency use is justified
- **BAMLANIVIMAB** has not been observed in patients hospitalized due to COVID-19
- **BAMLANIVIMAB** may adversely affect clinical outcomes for patients hospitalized due to COVID-19

**BAMLANIVIMAB** must be administered by IV infusion where there is immediate access to medications that treat severe allergic reactions such as anaphylaxis and where EMS can be activated if necessary.

For more information on clinical trials of **BAMLANIVIMAB** visit www.clinicaltrials.gov